JINYU(SH:600201)2017-04-24 16:00Financial Performance - Operating income rose by 34.54% to CNY 460,895,231.81 year-on-year[6] - Net profit attributable to shareholders increased by 37.98% to CNY 262,865,565.10 compared to the same period last year[6] - Basic earnings per share increased by 26.47% to CNY 0.43[6] - The diluted earnings per share also increased by 26.47% to CNY 0.43[6] - Total operating revenue for Q1 2017 was CNY 460,895,231.81, an increase of 34.5% compared to CNY 342,574,317.20 in the same period last year[26] - Net profit for Q1 2017 reached CNY 265,647,297.28, representing a 39.0% increase from CNY 191,098,217.05 in Q1 2016[27] Cash Flow - Cash flow from operating activities surged by 70.79% to CNY 163,215,396.30 year-on-year[6] - Cash received from sales of goods and services increased by CNY 93.29 million, up 37.13%, mainly due to higher collections from direct sales of biopharmaceuticals[15] - Cash received from other operating activities increased by CNY 8.06 million, a rise of 124.06%, primarily due to increased guarantee deposits received[15] - Total cash inflow from operating activities was ¥359,101,581.75, up from ¥257,751,364.33 in the previous period, reflecting an increase of about 39.3%[31] Assets and Liabilities - Total assets increased by 7.41% to CNY 4,670,013,609.58 compared to the end of the previous year[6] - Total liabilities at the end of Q1 2017 were CNY 920,113,980.20, up from CNY 872,686,263.68 at the start of the year[24] - Current assets totaled CNY 1,908,641,611.72, an increase from CNY 1,889,535,344.52 at the beginning of the year[22] - Cash and cash equivalents decreased to CNY 1,334,154,248.76 from CNY 1,388,434,082.83 at the start of the year[22] Shareholder Information - The number of shareholders reached 15,928 at the end of the reporting period[11] - The largest shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., holds 10.96% of shares, totaling 67,200,000 shares[11] Receivables and Revenue - Accounts receivable increased by CNY 125.51 million, a rise of 47.67%, mainly due to increased direct sales of vaccines in the biopharmaceutical sector and unsettled government procurement income[13] - Other receivables rose by CNY 24.41 million, an increase of 154.47%, primarily due to increased inter-company payments in the biopharmaceutical sector[13] - Revenue increased by CNY 118.32 million, up 34.54%, driven by higher direct sales of foot-and-mouth disease vaccines and porcine circovirus vaccines[13] Operating Costs - Operating costs increased by CNY 23.79 million, a rise of 33.94%, corresponding to the increase in vaccine sales[13] - Cash paid to employees increased by CNY 17.88 million, up 69.90%, mainly due to the payment of last year's performance bonuses[15] - Cash paid for taxes increased by CNY 10.62 million, a rise of 28.06%, primarily due to higher corporate income tax payments[15] Other Financial Metrics - The weighted average return on equity decreased by 2.00 percentage points to 6.85%[6] - The company reported non-recurring gains of CNY 3,117,577.44 during the reporting period[8] - The company reported an investment income of CNY 1,777,962.79, compared to CNY 266,637.79 in the previous year[27] - The company incurred asset impairment losses of ¥10,430,171.28, a significant rise from ¥1,359,262.84 in the previous period, representing an increase of approximately 669.5%[29]